Annie Lintzenich Andrews1, David G Bundy2, Kit N Simpson3, Ronald J Teufel2, Jillian Harvey3, Annie N Simpson3. 1. Department of Pediatrics, Medical University of South Carolina College of Medicine, Medical University of South Carolina College of Medicine, Charleston, SC. Electronic address: andrewsan@musc.edu. 2. Department of Pediatrics, Medical University of South Carolina College of Medicine, Medical University of South Carolina College of Medicine, Charleston, SC. 3. Department of Healthcare Leadership and Management, Medical University of South Carolina College of Health Professions, Charleston, SC.
Abstract
OBJECTIVE: To determine rates of inhaled corticosteroid (ICS) claims and outpatient follow-up after asthma hospitalization among commercially insured children. METHODS: We conducted a retrospective cohort analysis of children hospitalized for asthma using 2013 national Truven MarketScan data. Covariates included age, sex, region, length of stay, and having an ICS claim within 35 days before hospitalization. Outcome variables were a claim for any ICS-containing medication and outpatient visit within 30 days after discharge. Multivariable analysis used logistic regression. RESULTS: A total of 5471 children aged 2 to 17 were included; 61% were boys, and mean age was 6.8 years. Forty-one percent had a claim for an ICS and 76% had an outpatient visit within 30 days after hospital discharge. In multivariable analysis, children who had an ICS claim within 35 days before the hospitalization were more likely to have an ICS claim within 30 days after discharge (relative risk [RR] 1.3, 95% confidence interval [CI] 1.2-1.5). The strongest predictor of an ICS claim within 30 days after discharge was attendance at an outpatient appointment (RR 1.4, 95% CI 1.3-1.6). Children aged 2 to 6 were more likely to attend an outpatient appointment (RR 1.1, 95% CI 1.1-1.2). Children with an ICS claim before admission were also more likely to attend an outpatient appointment (RR 1.1, 95% CI 1.004-1.1). CONCLUSIONS: In this national sample of commercially insured children with asthma, rates of ICS claims after hospitalization are low despite high rates of outpatient visits. Both inpatient and outpatient physicians must play a role in increasing ICS adherence in this high-risk population of children with asthma.
OBJECTIVE: To determine rates of inhaled corticosteroid (ICS) claims and outpatient follow-up after asthma hospitalization among commercially insured children. METHODS: We conducted a retrospective cohort analysis of children hospitalized for asthma using 2013 national Truven MarketScan data. Covariates included age, sex, region, length of stay, and having an ICS claim within 35 days before hospitalization. Outcome variables were a claim for any ICS-containing medication and outpatient visit within 30 days after discharge. Multivariable analysis used logistic regression. RESULTS: A total of 5471 children aged 2 to 17 were included; 61% were boys, and mean age was 6.8 years. Forty-one percent had a claim for an ICS and 76% had an outpatient visit within 30 days after hospital discharge. In multivariable analysis, children who had an ICS claim within 35 days before the hospitalization were more likely to have an ICS claim within 30 days after discharge (relative risk [RR] 1.3, 95% confidence interval [CI] 1.2-1.5). The strongest predictor of an ICS claim within 30 days after discharge was attendance at an outpatient appointment (RR 1.4, 95% CI 1.3-1.6). Children aged 2 to 6 were more likely to attend an outpatient appointment (RR 1.1, 95% CI 1.1-1.2). Children with an ICS claim before admission were also more likely to attend an outpatient appointment (RR 1.1, 95% CI 1.004-1.1). CONCLUSIONS: In this national sample of commercially insured children with asthma, rates of ICS claims after hospitalization are low despite high rates of outpatient visits. Both inpatient and outpatient physicians must play a role in increasing ICS adherence in this high-risk population of children with asthma.
Authors: Chén C Kenyon; David M Rubin; Joseph J Zorc; Zeinab Mohamad; Jennifer A Faerber; Chris Feudtner Journal: J Pediatr Date: 2015-01-29 Impact factor: 4.406
Authors: Lara J Akinbami; Jeanne E Moorman; Cathy Bailey; Hatice S Zahran; Michele King; Carol A Johnson; Xiang Liu Journal: NCHS Data Brief Date: 2012-05
Authors: N Ewen Wang; Michael A Gisondi; Mana Golzari; Theresa M van der Vlugt; Methodius Tuuli Journal: Acad Emerg Med Date: 2003-11 Impact factor: 3.451
Authors: Anne M Fitzpatrick; Leonard B Bacharier; Theresa W Guilbert; Daniel J Jackson; Stanley J Szefler; Avraham Beigelman; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Wayne Morgan; Wanda Phipatanakul; Jacqueline A Pongracic; Robert S Zeiger; David T Mauger Journal: J Allergy Clin Immunol Pract Date: 2018-09-26
Authors: Shelagh M Szabo; Ishan Hirji; Karissa M Johnston; Ariadna Juarez-Garcia; Joseph M Connors Journal: PLoS One Date: 2017-10-09 Impact factor: 3.240